Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

doi:10.1186/bcr906

Breast Cancer Res

Volume 6
Issue 4

Viewing options:

Abstract
Full text
PDF (68KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Rutgers EJ
Meijnen P
Bonnefoi H

on PubMed

Rutgers EJ
Meijnen P
Bonnefoi H
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Commentary

Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

Emiel JT Rutgers¹ , Philip Meijnen² and Hervé Bonnefoi³

¹Chairman of the EORTC Breast Cancer Group and Principal Investigator of the EORTC 10981-22023 AMAROS trial, Department of Surgery, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

²Research Fellow and Coordinator of the EORTC 10981-22023 AMAROS trial, Department of Surgery, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

³Secretary of the EORTC Breast Cancer Group and Principal Investigator of the EORTC 10994 p53 trial, Department of Medical Oncology, University Hospital of Geneva, Switzerland

author email corresponding author email

Breast Cancer Res 2004, 6:165-169doi:10.1186/bcr906


Published:	16 June 2004

Abstract

The present clinical trial update consists of a review of two of eight current studies (the 10981-22023 AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is designed to prove equivalent local/regional control for patients with proven axillary lymph node metastasis by sentinel node biopsy if treated with axillary radiotherapy instead of axillary lymph node dissection, with reduced morbidity. The p53 trial started to assess the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane regimen versus a nontaxane regimen.